title: Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.
abstract: The development of inhibitors toward factor VIII (FVIII) is a common and serious complication of hemophilia A (HA) therapy. Patients with hemophilia who develop inhibitors often undergo time- and resource-intensive immune tolerance induction (ITI) protocols. We report a 15-month-old male with severe HA and a high-titer inhibitor that occurred while receiving prophylactic treatment with recombinant FVIII (rFVIII), in whom significant inhibitor titer reduction was achieved with thrice weekly infusions of a new, prolonged half-life rFVIII-Fc fusion protein product (trade name Eloctate). Further studies are warranted to explore the potential of Eloctate in ITI protocols.
authors.affiliation: Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.|Walter Reed National Military Medical Center, Bethesda, Maryland.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Groomes
authors.affiliation: Walter Reed National Military Medical Center, Bethesda, Maryland.
authors.forename: David M
authors.initials: DM
authors.lastname: Gianferante
authors.affiliation: Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.|Walter Reed National Military Medical Center, Bethesda, Maryland.
authors.forename: Gary D
authors.initials: GD
authors.lastname: Crouch
authors.affiliation: Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.|Walter Reed National Military Medical Center, Bethesda, Maryland.
authors.forename: Dina S
authors.initials: DS
authors.lastname: Parekh
authors.affiliation: Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.
authors.forename: David W
authors.initials: DW
authors.lastname: Scott
authors.affiliation: Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.|Walter Reed National Military Medical Center, Bethesda, Maryland.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Lieuw
mesh_terms: D019774:Blood Coagulation Factor Inhibitors / Q000276:immunology*; D003888:Desensitization, Immunologic; D005169:Factor VIII / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D007223:Infant; D008297:Male; D011961:Receptors, Fc / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; C078147:F8 protein, human; D005169:Factor VIII
keywords: eloctate; factor VIII inhibitors; hemophilia A; immune tolerance induction; recombinant factor VIII-Fc fusion protein